cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Immunitybio Inc
13 own
6 watching
Current Price
$2.96
$-0.09
(-2.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,290.33M
52-Week High
52-Week High
7.8
52-Week Low
52-Week Low
1.21
Average Volume
Average Volume
2.16M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,290.33M
icon52-Week High7.8
icon52-Week Low1.21
iconAverage Volume2.16M
iconDividend Yield--
iconP/E Ratio--
What does the Immunitybio Inc do?
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Read More
How much money does Immunitybio Inc make?
News & Events about Immunitybio Inc.
Business Wire
1month ago
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Executive Chairman and Global Chief Scientific and Medical Officer Patrick Soon-Shiong, M.D., has been invited to deliver the 2023 David Packard Award Lecture at the Uniformed Services University of the...
Business Wire
1month ago
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the opening of a clinical trial to study its investigational Tri-Ad5 vaccine combination (Adenovirus 5 CEA/MUC1/brachyury) together with its IL-15 superagonist N-803, an immune-enhancer, for people with a...
Business Wire
3 months ago
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced Dr. Karim Chamie, Associate Professor of Urology at UCLA, will be presenting Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RFc...
Business Wire
3 months ago
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with...
Business Wire
4 months ago
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results in its fully-enrolled metastatic pancreatic cancer study in third-line or greater subjects (QUILT 88) showing that the overall survival rate for patients continues to be double compared to...
Frequently Asked Questions
Frequently Asked Questions
What is Immunitybio Inc share price today?
plus_minus_icon
Can Indians buy Immunitybio Inc shares?
plus_minus_icon
How can I buy Immunitybio Inc shares from India?
plus_minus_icon
Can Fractional shares of Immunitybio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Immunitybio Inc stocks?
plus_minus_icon
What is today’s traded volume of Immunitybio Inc?
plus_minus_icon
What is today’s market capitalisation of Immunitybio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Immunitybio Inc?
plus_minus_icon
What percentage is Immunitybio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Immunitybio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.96
$-0.09
(-2.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
TRANSMEDICS GROUP INC
TRANSMEDICS GROUP INC
$80.01
$0.67 (0.84 %)
SI-BONE INC
SI-BONE INC
$27.48
$0.05 (0.18 %)
ORCHARD THERAPEUTICS PLC
ORCHARD THERAPEUTICS PLC
$4.97
$-0.11 (-2.17 %)
IMMATICS NV
IMMATICS NV
$10.79
$0.70 (6.94 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
TRANSMEDICS GROUP INC
TRANSMEDICS GROUP INC
$80.01
$0.67 (0.84 %)
SI-BONE INC
SI-BONE INC
$27.48
$0.05 (0.18 %)
ORCHARD THERAPEUTICS PLC
ORCHARD THERAPEUTICS PLC
$4.97
$-0.11 (-2.17 %)
IMMATICS NV
IMMATICS NV
$10.79
$0.70 (6.94 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00